AVTX   $13.67  1.86% Market Open

Avalo Therapeutics, Inc.
Total Cash 93.43M
totalCashPerShare 90.343
EBITDA -22.05M
Total Debt 1.73M
quickRatio 0.97
currentRatio 0.995
Total Revenue 807.00K
debtToEquity
Revenue/Share 1.114
ROA -0.20938
ROE
grossProfits
freeCashflow 77.20M
operatingCashflow -32.09M
earningsGrowth
revenueGrowth
grossMargins 0.0
ebitdaMargins 0.0
operatingMargins -27.51053
profitMargins 0.0
enterpriseValue -66.38M
forwardPE -2.4677715
floatShares 549.49K
sharesOutstanding 9.70M
sharesShort 49.24K
sharesShortPriorMonth 59.47K
dateShortInterest
sharesPercentSharesOut 0.01%
heldPercentInsiders 0.02%
heldPercentInstitutions 0.39%
Short Ratio help_outline 3.32%
shortPercentOfFloat 0.01%
impliedSharesOutstanding
bookValue -13.159
Price To Book help_outline
earningsQuarterlyGrowth
netIncomeToCommon -36.22M
trailingEps -7126.35%
forwardEps -5.43%
enterpriseToEbitda 3.01
lastDividendValue
lastDividendDate
currentQuarterEstimate -1.19 3Q 2024
institutionsCount 29
lastUpdated Nov. 7, 2024, 5:15 a.m.